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This review discusses the current status of proteomics technology in endometrial cancer diagnosis, 24 
treatment, and prognosis. The first part of this review focuses on recently identified biomarkers for 25 
endometrial cancer, their importance in clinical use as well as the proteomic methods used in their 26 
discovery. The second part highlights some of the emerging mass spectrometry based proteomic 27 
technologies that promise to contribute to a better understanding of endometrial cancer by 28 




Endometrial cancer (EC) is the most common malignant tumour of the female reproductive tract. 31 
According to the American Cancer Society, an estimated 52,630 new EC were diagnosed and 8,590 32 
patients died from the disease in 2014 in the USA. From 2006 to 2010, incidence rates of EC 33 
increased by 1.5% per year among women younger than 50 years and by 2.6% per year among 34 
women 50 years and older (1). Based on the classification system introduced by Bokhman in 1983, 35 
EC is divided into two histological subtypes: endometroid adenocarcinomas (Type I) and non-36 
endometroid (Type II) carcinomas (2). Type I adenocarcinomas account for 90% of all EC. These 37 
cancers are usually low grade, diagnosed at an early stage and have a good prognosis. They are 38 
associated with oestrogen excess, obesity and atypical hyperplasia. In contrast, type II non-39 
endometroid tumours are high grade tumours with more aggressive biological behaviour compared 40 
to type I disease. Clinically, type II cancers are often diagnosed at advanced stage when prognosis is 41 
poor. Type II tumours include serous, and clear cell carcinomas as well as carcinosarcomas. 42 
Proteomics, more precisely the comparative quantitation of protein subsets, holds great promise in 43 
improving outcome of patients with EC as it provides unique tools for discovery of new biomarkers 44 
and therapeutic targets. To date, biomarkers have proven their tremendous clinical value in early 45 
diagnosis (3, 4), categorizing different subtypes of malignancies (5, 6) and in monitoring patient’s 46 
response to therapy (7, 8). Regardless of the numerous proteomic studies that have contributed to 47 
the standardization of experimental protocols for digestion (9), separation (10), enrichment (11), 48 
identification (12) and quantification (13) of less abundant proteins by highly efficient mass 49 
spectrometric techniques, proteomic research is still restricted by both technology and 50 
bioinformatics tools. Many protein and peptide peaks have been reported to bear significant 51 
diagnostic (14), prognostic (15) or predictive value (16) for EC; however, the candidate biomarkers 52 
have not yet been validated for use in clinical patient care (17). Some authors have speculated that 53 
this might be due to studies using a single proteomics approach, which is not sufficient to gain an in 54 
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depth understanding of the protein function and does not eliminate false-negative and false-positive 55 
results (18). Nevertheless, implementing ‘omics’ integration approaches and the use of the rapidly 56 
emerging mass spectrometry based proteomic technologies will aid in the venture to elucidate 57 
protein markers and their function, ultimately providing more reliable, sensitive, and specific 58 
biomarkers for EC. 59 
In the first part of this review article we will summarize the various mass spectrometry based 60 
proteomic approaches that have been used in EC studies. In the second part, we will introduce 61 
emerging proteomic technologies which may not only be used as discovery tools but also allow the 62 
implementation of mass spectrometry in the diagnosis and prognosis of EC.  63 
1. Clinical considerations of endometrial cancer 64 
The clinical management of EC remains a challenge with patients presenting with a full spectrum of 65 
disease ranging from those with excellent prognosis and high curability to aggressive disease with 66 
poor outcome (19). EC is staged according to the International Federation of Gynaecology and 67 
Obstetrics (FIGO) system (Table 1) (20). The classification of EC into low and high risk disease is 68 
dependent on a number of parameters, only two of which are assessable pre-operatively 69 
[http://wiki.cancer.org.au/australiawiki/index.php?oldid=86682] after a biopsy has been obtained, 70 
namely the histological type and grade. However, Jacques et al. have shown a large percentage of 71 
cancer will be classified as a higher grade tumour after definitive surgery (21). Therefore, the exact 72 
type, grade and stage of EC can only be determined by surgery and subsequent histopathological 73 
assessment.  74 
1.1. Diagnosis  75 
EC is frequently diagnosed at an early stage, as it regularly presents with symptoms such as post-76 
menopausal bleeding which usually develops early in the disease process. Nevertheless, the 77 
discovery of serum biomarkers for early detection of EC has become a high priority (22). A number of 78 
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serum biomarkers has been identified so far, with the most commonly used serum biomarker in 79 
gynaecological oncology being Carbohydrate Antigen 125 (CA 125). In EC, an elevated serum CA 125 80 
level have been detected in 11-43% of the cases and is shown to be correlated with advanced stage 81 
and with the presence of extrauterine disease (23-25). However, due to lack of specificity and 82 
sensitivity, CA 125 has limited significance in the diagnosis of EC. Human Epididymis protein 4 (HE4) 83 
has recently emerged as a promising biomarker for EC (26). Brennan et al. highlighted the utility of 84 
serum HE4 using ELISA for pre-operative risk stratification to identify high-risk patients within low-85 
grade endometrioid EC patients who might benefit from lymphadenectomy (27). For stage I EC, HE4 86 
showed a 17% improvement in sensitivity when compared to CA 125 (28). 87 
Hareyama et al. investigated the immunohistochemical CA72-4 expression in EC. The authors 88 
reported an elevated level of serum CA72-4 in 22-32% of the cases, which is associated with depth of 89 
myometrial invasion, adnexal metastasis, lymphovascular space invasion, and pelvic and para-aortic 90 
lymph node metastasis (29). Konno et al. demonstrated the level of serum soluble Fas (sFas) is 91 
significantly higher in EC patients with advanced cancer when compared to localized cancer (p < 92 
0.0001) (30). A study by Sawada et al. showed the raised serum level of immunosuppressive acidic 93 
protein (IAP) in 55-76% of EC cases and the level increases with the stage of the disease (31). Hakala 94 
et al. reported the serum level of macrophage colony-stimulating factor 1 (mcsf 1), correlates 95 
significantly with tumour grade and poor prognosis in 25-73% of EC cases (32) (33). A recent study by 96 
Kang-Wai Mu et al. reported differential levels of zinc alpha-2 glycoprotein, alpha 1-acid 97 
glycoprotein, and CD59 in the urine of EC patients when compared to urine from healthy controls 98 
using Two Dimensional Gel Electrophoresis (2-DIGE) and O-Glycan binging lectin (34). 99 
1.2. Treatment  100 
EC is usually treated by surgery consisting of a hysterectomy, bilateral salpingo-oophorectomy and 101 
pelvic lymph node dissection and has a very good prognosis when it is confined to the uterus (28). In 102 
contrast, EC with metastasis to the lymph nodes has a high mortality rate. Lymph node metastasis is 103 
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therefore a crucial factor in the prognosis and choice of treatment of EC patients. Clinicians 104 
presently face the challenge that conventional surgical-pathological variables (e.g. tumour size, 105 
depth of invasion and grade of disease) and radiological imaging are unreliable in determining if a 106 
gynaecological cancer has spread. Consequently, although only 5% of patients suffer from 107 
metastasis, the majority undergo radical treatment including removal of the lymph nodes. Lymph 108 
node dissection, however, is associated with significant complications such as lower extremity 109 
lymphoedema (35). Predictive tissue markers for lymph node metastasis are therefore warranted to 110 
determine the optimal treatment strategy and to avoid morbidity in gynaecological cancer.  111 
1.3. Prognosis  112 
The prognosis of EC depends on various factors including the histological subtype, grade and stage of 113 
the disease (which is determined by depths of tumour invasion, lymph node metastasis and spread 114 
of the disease to other organs) (36). The depth of myometrial invasion and histological grade 115 
strongly correlate with the prevalence of lymph node metastasis and patient survival (37).   116 
Various protein biomarkers have been described in EC that could be of benefit for the prediction of 117 
disease outcome. According to Cocco et al. serum amyloid A (SAA) may represent a novel biomarker 118 
for EC to monitor disease recurrence and response to therapy (38). Lo SS et al. shown the increased 119 
levels of CA125, CA15.3 and CA19.9 were significantly associated with poor prognostic clinical 120 
parameters (39). Lambropoulou et al. evaluated the prognostic significance of survivin, c-erbB2, and 121 
COX-2 levels in EC and stated that in a 10-year follow-up, patients with tumors expressing more of 122 
these three antigens had significantly lower survival rate that those with smaller expression score 123 
(40). Yilmaz et al. have also shown higher nuclear expression of survivin in type I when compared to 124 
type II EC (p=0.040); but no difference for cytoplasmic survivin and matrix metalloproteinase-2 125 
expressions between type I and type II EC (41). Zeimet et al., identified L1 cell adhesion molecule 126 
(L1CAM) as the best variable for predicting recurrence (sensitivity = 0.74; specificity = 0.91) and 127 
death (sensitivity = 0.77; specificity = 0.89) (42). Although, the above mentioned biomarkers are able 128 
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to identify high risk patients with low grade EC, for clinical application additional biomarkers are 129 
required. New prognostic EC biomarkers will help distinguish patients who are at a low-risk of 130 
developing metastasis as compared to those who are at a high risk. Ideally, novel biomarkers will 131 
also be able to distinguish patients who have already developed metastasis. This would 132 
consequently allow patients to selectively undergo radical surgery while avoiding those who will not 133 
benefit from it and subsequently decreasing the risk of post-surgical morbidity.  134 
2. Molecular Genetics of endometrial cancer 135 
Aside from the morphologic and clinical features, EC can be further distinguished into type I and type 136 
II EC on the basis of genetic alterations (43). Type I and type II ECs are associated with mutations of 137 
independent gene sets (44). Type I endometrial adenocarcinomas are characterized by mutations in 138 
the PTEN, K-ras and β catenin, as well as DNA mismatch repair genes (35) while type II non-139 
endometrioid EC frequently shows aneuploidy and p53 mutations (35). 140 
PTEN has been reported to be the most frequent genetic alteration of type I EC. PTEN, a tumour 141 
suppressor gene has been altered in up to 83% of endometrial adenocarcinoma and 55% in pre-142 
cancerous lesions (45). Microsatellite instability (MSI) has been demonstrated in 20% of type I EC 143 
(46). According to Bilbao et al. both PTEN mutations and MSI represent early events in endometrial 144 
carcinogenesis (47). Other genetic alterations that occur in type I EC include mutations in K-ras (48) 145 
and β catenin (49). PTEN, MSIS and K-Ras mutations often coexist with each other, whereas 146 
mutations in β-catenin are usually observed alone (50).  147 
The most common genetic alteration in type II EC is in p53, the tumour suppressor gene with an 148 
occurrence of 93% mutations in p53 in type II EC (48, 51). Other frequent genetic alteration in type II 149 
ECs are inactivation of the tumour suppressor gene p16 and over-expression of the oncogene, HER-150 
2/neu (52).     151 
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3. Metastasis and protein biomarker 152 
Metastatic cancer cells proliferate, lose contact with neighbouring cells, migrate through interstitial 153 
matrix, invade blood and lymph vessels and grow out again into lymph nodes or distant organs (53). 154 
Most cancer cells fail to undergo metastasis due to deficiency in one of the required steps like 155 
invasion, detachment, and survival (54). Discovery of EC biomarkers would significantly aid 156 
gynaecological oncologists who currently face the challenge that radiological imaging and 157 
conventional surgical-pathological variables such as tumour size, depth of invasion and grade of 158 
disease are unreliable in determining if an EC has metastasized.   159 
The working model of metastasis implies that primary tumour cells acquire genetic alterations over 160 
time, which enables these cells to metastasize and form new solid tumours at distant sites (55). It 161 
has been proposed that the gene expression program of metastasis is actually present in the bulk of 162 
primary tumour cells (56). Ramaswamy et al. shown some primary tumours are preconfigured to 163 
metastasize, and their susceptibility is detectable at the time of diagnosis. They defined a 17-gene 164 
signature pattern associated with metastasis, in which eight genes are up-regulated, while nine 165 
genes are down-regulated. They also concluded that metastasis is not dependent on only a single 166 
gene but on the complete 17 gene sequence.    167 
Yi et al., shown the expression of cyclooxygenase (COX-2) plays an important role in metastasis of EC 168 
(57). They identified the COX-2 inhibitor NS-398 inhibits proliferation, viability and invasion of the EC 169 
cell line RL95–2 (57). Maxwell et al. confirmed annexin A2 (ANXA2) and peroxiredoxin (PRDX1) were 170 
both being overexpressed in stage 1 EC when compared to normal endometrium (58).                                                                                                  171 
4. Mass Spectrometry based proteomic approaches in endometrial cancer 172 
The use of proteomic technologies are now enabling the identification and relative quantification of 173 
multiple proteins simultaneously from a single experiment to identify disease related and specific 174 
biomarkers. Proteomics in general deals with the large-scale determination of gene and cellular 175 
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function directly at the protein level (59). The proteome has also been defined as the protein 176 
complement expressed by a genome (60) but in reality, due to post-translational modifications and 177 
alternative splicing, it is estimated that about 22,000 protein coding genes (61) code for more than 178 
500,000 proteins (62) in the human proteome.  179 
In serum it is estimated that cancer derived proteins are 10 million times less abundant than 180 
common high abundant proteins secreted by normal cells. Therefore, it is challenging to correctly 181 
identify and quantify tumor derived proteins from the whole serum proteome (63). Alternatively, it 182 
is obvious that cancer derived proteins will be present in higher concentration in native tissue, 183 
organs and their proximal fluids from where the tumor has originated as compared to the distant 184 
sites in which the tumor derived proteins may be secreted or leaked. Therefore, targeting those 185 
regional sites will dramatically increase the possibility of isolating and identifying tumor specific 186 
biomarkers (64).  187 
Proteomic analysis principally relies on mass spectrometry (MS) for protein identification. The uses 188 
of MS based techniques have made it possible to build comprehensive profiles of near complete 189 
proteomes, comparing the expressions of individual proteins that may serve as biomarkers. 190 
Generally, MS based proteomic techniques can be classified as ‘gel based’ and ‘gel free’ (Figure 1). In 191 
gel based approaches such as One Dimensional Polyacrylamide Gel Electrophoresis (1D-PAGE), Two-192 
Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE) and Two-Dimensional Differential Gel 193 
Electrophoresis (2D-DIGE), proteins are separated on polyacrylamide gels via electrophoresis in one 194 
or two dimensions, creating unique proteomic patterns based on the mass and/or charge/pH of the 195 
proteins. 196 
Gel free MS approaches can be either label based or label free. Label based proteomic techniques 197 
are common for mass spectrometry approaches where proteins are tagged either with isotopes such 198 
as isotope coded affinity tags (ICAT), isobaric tags for relative and absolute quantification (iTRAQ) or 199 
labelled chemically such as stable isotope labelling by amino acids in cell culture (SiLAC). Labelling 200 
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facilitates the quantification of proteins during MS analysis and is especially useful when acquiring 201 
data in the standard form of data dependent acquisition (DDA), as labelling allows for the mixing and 202 
analysis of multiple samples at one. This alleviates the stochastic nature of DDA which can otherwise 203 
lead to sampling biases and poor reproducibility. Label free techniques in the form of data 204 
independent acquisition (DIA) help resolve the issue of sampling biases and eliminates any problems 205 
encountered due to artifacts from labelling which can interfere with the identity of the protein, 206 
leading to false conclusions (65, 66). DIA is addressed in more depth later in this article. 207 
MS based proteomics techniques have developed substantially over the past several years. 208 
Previously, protein analysis was reliant on 1D and 2D gel electrophoresis followed by sequencing; 209 
finally resulting in the identification of tens to hundreds of proteins. This limitation has been 210 
overcome with novel mass spectrometric approaches, which can identify many more proteins at 211 
once. Identification and quantification of proteins/peptides by MS can be done either by ‘bottom-212 
up’ or ‘top-down’ approaches. The term ‘bottom-up’ refers to the reconstruction of the protein 213 
sequence after proteolytic digestion, and thereby, identification and quantification of the peptide 214 
fragments using mass spectrometry and appropriate databases (67). The second approach ‘top-215 
down’, refers to the identification of the whole proteins directly without enzymatic digestion (68). 216 
To date, the most widely used proteomic technologies applied to the identification of the EC 217 
biomarkers includes liquid chromatography coupled online/offline with MS (LC-MS). This approach is 218 
generally used with ‘bottom-up’ methods. LC-MS has been used to identify and quantify differential 219 
change in protein abundance in healthy versus disease state. Identification of proteins by LC-MS/MS 220 
can be broken down into a few essential components. First, complex protein samples are digested 221 
with an enzyme (protease) into peptides, which are separated by a high resolution chromatographic 222 
technique coupled directly to a MS. Following chromatographic separation samples are sprayed into 223 
the MS whilst being ionised, a process called Electrospray ionisation (ESI). Here the intact peptide 224 
mass is measured, followed by collision with an inert gas to induce fragmentation, upon which the 225 
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mass of the fragment ions are measured. The acquired data is then processed to gain peptide 226 
sequences and protein identifications, and examined using mathematical algorithms, functions to 227 
detect and identify differences within the sample and/or between the samples. In traditional label 228 
free approaches, peptide separation is compared across chromatographic profiles, and quantitation 229 
is determined either by spectral counting or by peak intensity during MS (69).  230 
A recent study by Alconada et al. has identified and validated annexin (ANXA2) as a reliable 231 
biomarker of recurrent disease in EC by 2D DIGE followed by traditional LC-MS/MS. They 232 
demonstrated in vitro and with an in vivo mouse model that the increased expression of ANXA2 is 233 
associated with an improved ability of the cells to metastasise (70). Monge et al. analysed the role of 234 
the transcription factor ERM/ ETV5 in myometrial invasion by 2D-DIGE to evaluate the differential 235 
expression of proteins in EC cell lines overexpressing ERM/ETV5 (71). The authors have 236 
demonstrated that ERM/ETV5 acts by involving matrix metalloproteinase-2 to provide the migratory 237 
and invasive capabilities associated with the switch to myometrial infiltration in Hec-1A EC cell line 238 
(71). They further characterized a role for ETV5 in a modulated response to oxidative stress 239 
associated with the promotion of invasion in EC (71). Ihata et al. analysed the amino acid 240 
concentrations in plasma samples by LC-MS and reported that the amino acid profile index (API) is a 241 
potential new modality that could eventually play a significant role in the preoperative evaluation of 242 
EC and its screening (72). 243 
The matrix assisted laser desorption/ionisation (MALDI) technique has also been widely used for the 244 
discovery of gynaecological cancer biomarkers but in a more limited context for EC. Qiu et al. have 245 
reported that MALDI-Time of flight (TOF) MS is a high-throughput, sensitive, highly predictive and 246 
rapid method for the early detection, diagnosis and prognosis of EC and will be widely used in future 247 
clinical screening work (73). In this technique, molecules including proteins, peptides, lipid and 248 
metabolites, are first co- crystallized with large excess of suitable matrix (usually a weak organic 249 
acid) and then spotted on to a MALDI target plate. MALDI TOF MS is then performed, a process in 250 
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which the laser transfers the energy to the aromatic matrix molecules and the matrix transfer a 251 
proton to the analyte, resulting in soft energy transfer without fragmentation. According to the mass 252 
to charge (m/z) ratios, the ionised analytes are then separated in the  time-of flight mass analyser 253 
and the detector transforms the incoming ions into an electric current which is proportional to their 254 
abundance (74). In the case of protein analysis, the generated protein/peptide mass list can then be 255 
compared to protein databases that allow for the matching of peptide masses and identification of 256 
proteins. Casado-Vela et al. used an integrated approach combining three different but 257 
complementary strategies (in-solution digest followed by reverse phase HPLC-MS/MS, protein 258 
separation by SDS-PAGE followed by HPLC-MS/MS analysis, 2D-PAGE followed by MALDI-259 
TOF/TOF analysis) to describe comprehensive proteomic analysis of EC fluid aspirate which led to the 260 
successful identification of 803 different proteins in the International Protein Index (IPI) human 261 
database (v3.48) (75). Therefore, EC biomarkers can be used for screening, estimating risk of disease, 262 
distinguishing benign from malignant, determining prognosis, and monitoring status of the disease, 263 
either to detect recurrence or response to therapy. Importantly, some biomarkers are only used in a 264 
specific setting, whereas others can serve more than one purpose (76). 265 
5. Emerging techniques for the proteomic analysis of endometrial cancer 266 
Traditional proteomic approaches as described above, continue to be the most widely applied 267 
technologies for protein identification; nonetheless, a major drawback of these proteomics 268 
techniques is that not every peptide from a complex biological sample can be detected. As a result, 269 
the proteomes will be under sampled. New techniques are emerging that offer innovative solutions 270 
to the analysis of low abundant proteins from complex biological samples (77). Those proteomics 271 
technologies have the potential for direct clinical applications including the identification of novel 272 
biomarkers for the monitoring of therapy response, and disease progression, delivering on the great 273 
promise of personalized cancer medicine (78).  274 
5.1. Data Independent Acquisition (DIA) 275 
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Protein identification by LC-MS is a straightforward technique, as the detection of only two unique 276 
peptides from a protein is considered sufficient. However, relative quantification by LC-MS is a more 277 
complex process and the failure to identify or detect a peptide does not necessarily confirm 278 
absence, as the peptides may simply be below the threshold of detection (79). Traditional LC-MS or 279 
shotgun approaches are based on Data dependent acquisition (DDA), where peptides are selected 280 
for isolation and fragmentation based on their relative abundance within the sample. This makes the 281 
technique stochastic and can result in under sampling of the injected analyte (80). Abundance 282 
measurements can be inaccurate as the quantification of a peptide is highly influenced by co-eluting 283 
peptides and their signal to noise ratios, meaning peptides of a higher abundance are quantified 284 
more accurately and more often than peptides of low abundance. We do however; know that many 285 
cancer-relevant proteins including signalling and regulatory proteins are typically expressed in low 286 
concentrations. As a result, the DDA approach tends to miss out on acquiring the most-valuable 287 
information (81). Data independent acquisition (DIA) aims to solve the problem of DDA by measuring 288 
all precursor ions within a defined mass range of ~25 Da, fragmenting and measuring all of the ions 289 
within that mass range (82). Typically a 25 Da mass window is stepped across the entire mass range 290 
covered in traditional LC-MS/MS (~150-2200 Da) in cycle times compatible with the coupled 291 
chromatographic separation (82). Vowinckel et al. shown the number of precisely quantifiable 292 
peptides can be increased up to 5 fold when using DIA compared to DDA, with a coefficient of 293 
variation (CV) less than 5% (83). 294 
5.2. MALDI Imaging (MALDI-MSI) 295 
Another innovative technology that can be used for both biomarker discovery and validation is 296 
MALDI imaging (MALDI-MSI), which facilitates the direct analysis of protein distribution and 297 
abundance in thin tissue sections (84). This technique has the potential to detect and characterize 298 
tumour margins and their environment in a spatial context (56). MALDI-MSI is a valuable method for 299 
the identification of biomarkers and can complement histology, immunohistochemistry (85) and 300 
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molecular pathology in various fields of histopathological diagnostics, especially with regard to 301 
identification and grading of tumors (86). Whereas, MALDI-MSI is optimally suited to detect a large 302 
number of molecular features in a given tissue sample, the tissue microarray (TMA) method enables 303 
expansion of this analysis to hundreds of tissue samples in a single experiment (87, 88). In MALDI-304 
MSI, proteins are directly ionised from the surface of the tissue sample and a characteristic 305 
histological pattern is derived for hundreds or thousands of individual peptides simultaneously, 306 
which may be further investigated and identified in the same tissue section by in-situ MS/MS (89). 307 
During MS/MS, a desired peptide is isolated based on its m/z ratio and fragmented (i.e. breaking 308 
peptide bonds within the peptides), producing a series of fragment ions that are detected as a 309 
MS/MS spectrum. The fragmentation pattern is compared to the theoretical fragmentation pattern 310 
for every peptide in the proteome to find the closest match. In this way the sequence of the peptide 311 
ion is inferred from its fragmentation pattern (90). Realistically in the case of MALDI-MSI, this form 312 
of tandem mass spectrometry is limited to highly abundant ionisable peptides whereas the 313 
identifications of lower abundance peptides can be made by matching back to fragmentation spectra 314 
acquired using LC-MS/MS.  315 
 MALDI-MSI has been successfully used to classify HER2 receptor expression in breast cancer (91). 316 
Meding et al. have shown the power of MALDI-MSI in classification of metastasis for different 317 
tumour entities (92). In addition, their results indicated that even closely related entities such as 318 
primary tumour of the colon and its liver metastasis could be classified efficiently (92). Quaas et al. 319 
detected several molecular signals associated with phenotypic features of oesophageal cancer cells, 320 
highlighting the potential of MALDI-MSI to identify new molecular markers with relevance to 321 
oesophageal cancer (87). Another strength of MALDI-MSI is that it can be used in the discovery 322 
phase for the identification of tumor derived proteins and then the verification of the presence of 323 
those particular proteins can be carried out in body fluid (blood, urine or saliva), aiming to develop 324 
non-invasive diagnostic tests. Addona et al. developed a pipeline integrating proteomic technologies 325 
from the discovery to the verification stages of plasma biomarker identification and applied it to 326 
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identify early biomarkers of cardiac injury (93). Thus, combining the histopathology reports with 327 
MALDI-MSI data will help surgeons to make right medical decisions. 328 
In the similar approach, we performed MALDI imaging on EC formalin fixed paraffin embedded 329 
(FFPE) tissue samples collected from the Royal Adelaide Hospital (RAH), South Australia. Ethics 330 
approval was granted by RAH Human ethics committee.  331 
In this study 6µm FFPE tissue sections were sliced and mounted onto indium tin oxide (ITO) coated 332 
conductive glass slides (Bruker Daltonics, Bremen, Germany) and samples were prepared as 333 
described by Gustafsson et al. (12). Briefly upon Citric acid antigen retrieval (CAAR), in-situ tryptic 334 
digestion was performed using an Image prep station (Bruker Daltonics, Bremen, Germany) at 37°C 335 
for 2 hours. α-Cyano-4-hydroxycinnamic acid (CHCA) matrix solution was prepared at 7mg/ml in 50% 336 
ACN/ 0.2% TFA and was overlayed onto the tissue section using an Image Prep station. Following 337 
matrix deposition, analyses was performed on an UltrafleXtreme MALDI-TOF/TOF (Bruker Daltonics, 338 
Bremen, Germany) in positive reflectron mode with FlexControl V3.0.1 and FlexImaging V4.0.1 339 
(Bruker Daltonics) software package. The data was acquired at 100μm lateral resolution with a laser 340 
frequency of 2000 Hz over m/z 800–4500. Following MS acquisition, an overlapped MALDI spectral 341 
profile of tumour and healthy regions was generated by FlexAnalysis software (V4.0.1, Bruker 342 
Daltonics, Bremen, Germany) and as expected, a number of m/z values have been identified which 343 
are differentially expressed between healthy and tumour regions (Figure 2). 344 
In order to determine data dependent visualization of tissue morphological regions, the raw data 345 
was loaded into SCiLS lab software (V2014b, Bruker Daltonics, Bremen, Germany). Data was 346 
processed by baseline removal and total ion count (TIC) normalization. Healthy and tumour regions 347 
were then grouped based on annotations done by a pathologist and discriminatory m/z values were 348 
calculated by ROC (Receiver operating characteristic) curve. ROC curve compares sensitivity verses 349 
specificity across a range of m/z values by plotting a curve called as Area under the ROC curve (AUC). 350 
The AUC assumes values between 0 and 1 and expresses the discrimination power of the m/z signal. 351 
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A perfect discrimination would yield an AUC value equal to 1 (abundant in group 1) or 0 (abundant in 352 
group 2) (94). The AUC closer to 0.5 indicates that there is no discrimination between two sample 353 
groups. An example of a discriminatory m/z value (m/z 1111.553Da ± 0.250Da) is shown in Figure 3. 354 
Here the spatial intensity of m/ z 1111.553Da ± 0.250Da is clearly higher in the healthy tissue regions 355 
as compared to the tumour tissue region, shown also in the ROC curve (Figure 4). The results from 356 
this study will provide crucial new tools to assist in the diagnosis and prognosis of EC, with the 357 
ultimate aim to prevent overtreatment of patients whose primary tumours do not have metastatic 358 
potential.  359 
5.3. Targeted Approach 360 
Sensitive detection of low abundant proteins in complex samples has been typically achieved by 361 
enzyme-linked immunosorbent assay (ELISA) which require antibodies specific to the protein(s) of 362 
interest. However, this poses a problem as development of antibodies is associated with high cost, 363 
long development lead times, and high failure rates (95). To overcome this problem, for the past few 364 
decades intensive research has been carried out aiming to develop more targeted strategies that 365 
have been designed specifically to analyse preselected peptides/proteins of interest within complex 366 
samples. 367 
Unlike untargeted approach, which aims to detect all proteins within a complex sample in an 368 
unbiased manner, Multiple reaction monitoring (MRM) is a targeted approach, in which the 369 
protein(s) of interest are preselected for quantification and analysed using highly sensitive triple 370 
quadrupole MS (96). MRM-MS provides high sensitivity and accuracy needed in the discovery phase 371 
and offers high reproducibility necessary for clinical validation (97). Due to the high specificity, 372 
sensitivity and throughput of MRM, it can be used for the validation of a single protein of interest or 373 
a subset of proteins (98). To ensure good quantification by MRM, three of the most intense ion 374 
transitions (precursor ion fragmentation to product ions) per protein are monitored. DeSouza et al. 375 
shown the MRM of iTRAQ labelled peptides enables absolute quantification of pyruvate kinase in 376 
17 
 
cancerous and normal endometrial tissues (99). Elizabeth et al. pioneered a new technique that 377 
couples the ability to perform MRM on a triple quadrupole mass spectrometer with a MALDI source 378 
(100). The authors have shown that this approach has the feasibility for the precise and accurate 379 
quantitation of tissue protein concentrations over 2 orders of magnitude, while maintaining the 380 
spatial localization information for the proteins (101). The greatest advantage of the MALDI MRM-381 
based imaging technique is improved sensitivity and selectivity of the analysis, enabling 382 
measurement of the accurate protein concentration with the addition of stable isotope labelled 383 
internal standards. This technique combines the spatial information gained by traditional MALDI MSI 384 
with the accurate quantification achievable by MRM and may develop to be an optimal strategy for 385 
the analysis of abundant peptide biomarkers. 386 
6. Conclusion 387 
Above mentioned studies have discovered a number of candidate EC biomarkers, for example CA-388 
125, CA 19-9, CA 15-3, HE4 for the diagnosis and L1CAM, COX-2, Survivin, c-erb B2 for the prognosis 389 
of EC. Unfortunately due to their lack in sensitivity and specificity none of those protein biomarkers 390 
are currently used in clinical practice. Recently, the major focus of biomarker research has shifted 391 
from single biomarker discovery to the multiparametric analysis of proteins, as the proteomic 392 
pattern analysis can obtain exceptional results. As part of this review we have introduced two 393 
emerging techniques with exceptional sensitivity and dynamic range. These techniques are refining 394 
our capability to identify and quantify relative changes in protein expression and will ultimately 395 
result in the discovery of new EC biomarkers panels.  396 
Moreover, the integration of the data obtained from various ‘omics’ approaches  such as genomics, 397 
transcriptomics and proteomics will help to reduce the false positives and false negatives obtained 398 
from single ‘omic’ approaches and provide us with a number of potential protein targets. Taken 399 
together, this is an exciting time for EC biomarker research and we are hopeful that novel EC 400 
biomarker panels will perform well and will be used in the clinic in the future.   401 
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Figure 1: Proteomic approaches used in the EC biomarker discovery: Gel based and Gel free. In Gel 686 
based proteomic approaches, proteins are separated on the basis of their charge/pH or mass by 687 
isoelectric focussing and electrophoresis. Gel free techniques include MS based technologies.  688 
Figure 2: In this analysis  in-situ tryptic digestion was performed on 6µm thick FFPE tissue. The 689 
matrix used was α-cyano-4-hydroxycinnamic acid and data was collected in positive reflectron mode 690 
using an UltrafleXtreme MALDI-TOF/TOF (Bruker Daltonics, Bremen, Germany). An overlapped 691 
MALDI spectral profiles of tumour and healthy regions was generated by FlexAnalysis software 692 
(V4.0.1, Bruker Daltonics, Bremen, Germany). (a) The overlapped spectral profile show a multitude 693 
of differentially expressed m/z species between healthy and tumor regions simultaneously that 694 
allows a straightforward correlation of the expression pattern within the tissue morphology (b) 695 
Comparative representative spectra of m/z 1111.553Da ± 0.250Da between healthy and tumor 696 
regions” 697 
Figure 3: MALDI-MSI of a EC FFPE sample. The expression pattern of  m/z 1111.553Da ± 0.250Da is 698 
visualized between healthy and tumour regions (B), when comparison is made with corresponding 699 
haematoxylin and eosin (H & E) stained annotated image (A). Visualization of difference in the 700 
intensities was performed in SCiLS lab software (V2014b, Bruker Daltonics, Bremen, Germany) with 701 
edge preserving image denoising and automatic hotspot removal applied. This m/z species is seen to 702 
be specifically downregulated in tumour region as comapre to healthy region. 703 
Figure 4: The ROC curve of m/z 1111.553Da ± 0.250Da (AUC = 0.985) for healthy versus tumour 704 
region  705 
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Table 1: Classification of carcinoma of the endometrium, International Federation of Gynaecology 706 
and Obstetrics (FIGO 2010), Table modified from Creasman et al. (102) 707 
FIGO stage Tumour localisation 
Stage I Tumour confined to the corpus uteri 
IA No or less than half myometrial invasion 
IB Invasion equal or more than half of the myometrium 
Stage II Tumour invades cervical stroma, but does not extend beyond the uterus 
Stage III Local and/or regional spread of the tumour 
IIIA Tumour invades the serosa of the corpus uteri and/or adnexa 
IIIB Vaginal and/or parametrial involvement 
IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IIIC1 Positive pelvic nodes 
IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph nodes 
Stage IV Tumour invades bladder and/or bowel mucosa, and/or distant metastasis 
IVA Tumour invades bladder and/or bowel mucosa 
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